Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Last trade$0.92
Day change-$0.09 (-8.91%)
Day range$0.905 – $1.06
Volume59,717
Market cap$10M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$10.14M
Price / earnings
—
Price / book
0.45×
Price / sales
—
EV / sales
—
EV / EBITDA
0.54×
Profitability
Earnings per share
-$2.58
Return on assets
-86.93%
Return on equity
-115.34%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.44×
Quick ratio
4.44×
Cash ratio
4.24×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$24.62M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CLRB, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.67M
$2.64M
$2.79M
$2.53M
$2.33M
$3.65M
$2.97M
$6.54M
Research and development
$5.44M
$4.56M
$3.01M
$3.16M
$2.52M
$2.39M
$3.43M
$6.21M
Total operating expenses
$8.1M
$7.2M
$5.79M
$5.69M
$4.85M
$6.04M
$6.4M
$20.49M
Operating income
-$8.1M
-$7.2M
-$5.79M
-$5.69M
-$4.85M
-$6.04M
-$6.4M
-$20.49M
Interest expense
$179.27K
$0
$63K
$0
$112.54K
$0
$136.96K
$0
Income before taxes
-$7.97M
-$6.93M
-$5.65M
-$5.3M
-$4.44M
-$5.45M
-$6.6M
-$2.29M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$66K
Net income
-$7.97M
-$6.93M
-$5.65M
-$5.3M
-$4.44M
-$5.45M
-$6.6M
-$2.36M
Net income attributable to common shareholders
-$7.97M
-$6.93M
-$5.65M
-$5.3M
-$4.44M
-$5.45M
-$6.6M
-$2.36M
EBITDA
-$8.07M
-$7.16M
-$5.9M
-$5.64M
-$4.8M
-$5.98M
-$6.34M
-$20.42M
Basic earnings per share
-$0.46
-$0.57
-$1.33
-$1.28
-$1.41
-$3.39
-$4.30
-$1.68
Diluted earnings per share
-$0.46
-$0.57
-$1.33
-$1.28
-$1.41
-$3.39
-$4.30
-$1.68
Recent news
Company coverage with links to the original publishers.
The Waldenstrom macroglobulinemia market is experiencing steady growth driven by advances in targeted therapies, particularly BTK inhibitors. Rising awareness, improved diagnostics, and increasing clinical trials are propelling market expansion, with several emerging drugs showing promise in treating this rare lymphoma.
Cellectar Biosciences, Inc. announced that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing restated financial statements for 2022, 2023, and the first half of 2024.
Cellectar Biosciences, Inc. announced that it needs to restate its previously issued financial statements due to a review of its accounting treatment for warrants issued in a 2022 financing. The company has received a delinquency notification from Nasdaq and has 60 days to submit a plan to regain compliance.